Leerink Partnrs Has Pessimistic Outlook of RYTM Q2 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Equities researchers at Leerink Partnrs lowered their Q2 2025 earnings per share estimates for Rhythm Pharmaceuticals in a research report issued on Sunday, July 13th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings of ($0.88) per share for the quarter, down from their prior estimate of ($0.86). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. Leerink Partnrs also issued estimates for Rhythm Pharmaceuticals’ Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($1.06) EPS, FY2025 earnings at ($3.73) EPS, Q1 2026 earnings at ($0.97) EPS, Q2 2026 earnings at ($0.92) EPS, Q3 2026 earnings at ($0.80) EPS and FY2026 earnings at ($3.30) EPS.

RYTM has been the topic of several other research reports. JMP Securities reiterated a “market outperform” rating and set a $84.00 price objective on shares of Rhythm Pharmaceuticals in a report on Thursday, June 26th. Bank of America upped their price target on Rhythm Pharmaceuticals from $73.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, July 10th. The Goldman Sachs Group began coverage on Rhythm Pharmaceuticals in a report on Thursday, July 10th. They issued a “buy” rating and a $97.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $95.00 price objective (up previously from $72.00) on shares of Rhythm Pharmaceuticals in a report on Wednesday, July 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 target price (up from $70.00) on shares of Rhythm Pharmaceuticals in a report on Tuesday, April 8th. Fourteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $91.00.

Rhythm Pharmaceuticals Stock Up 2.3%

Shares of NASDAQ RYTM opened at $91.44 on Wednesday. The firm has a market cap of $5.82 billion, a PE ratio of -32.54 and a beta of 2.26. The company’s fifty day simple moving average is $65.90 and its 200 day simple moving average is $59.97. Rhythm Pharmaceuticals has a 12-month low of $40.61 and a 12-month high of $94.80.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.12). The company had revenue of $37.72 million for the quarter, compared to analyst estimates of $40.43 million. Rhythm Pharmaceuticals had a negative return on equity of 739.62% and a negative net margin of 123.26%. The business’s quarterly revenue was up 25.9% compared to the same quarter last year. During the same period last year, the business earned ($2.35) EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its position in Rhythm Pharmaceuticals by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 440,250 shares of the company’s stock worth $24,645,000 after purchasing an additional 6,384 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter worth $218,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter worth $341,000. Swiss National Bank boosted its holdings in shares of Rhythm Pharmaceuticals by 1.0% in the 4th quarter. Swiss National Bank now owns 90,200 shares of the company’s stock worth $5,049,000 after buying an additional 900 shares during the last quarter. Finally, Cibc World Markets Corp bought a new position in Rhythm Pharmaceuticals during the fourth quarter valued at about $287,000.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, insider Joseph Shulman sold 7,969 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $77.78, for a total value of $619,828.82. Following the completion of the sale, the insider directly owned 8,509 shares of the company’s stock, valued at approximately $661,830.02. This represents a 48.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Pamela J. Cramer sold 15,572 shares of the firm’s stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $77.13, for a total value of $1,201,068.36. Following the transaction, the insider owned 19,209 shares in the company, valued at approximately $1,481,590.17. This trade represents a 44.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 93,673 shares of company stock valued at $7,118,510 in the last three months. Insiders own 6.10% of the company’s stock.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.